Mechanism of network pharmacology of Xiaoyao Powder and Kaixin Powder in treating depression with “Same disease with different treatments” / 中草药

ABSTRACT

Objective: The network pharmacology method was used to predict the active components, targets, and mechanism of Xiaoyao Powder and Kaixin Powder, and to explore the molecular mechanism of depression “same disease with different treatments”. Methods: TCMID, Batman-TCM, and TCM database@Taiwan were used to predict the targets and ingredients of Xiaoyao Powder and Kaixin Powder. The prediction was made via screening out the antidepressive drug targets approved by TTD, PharmGkb, CTD, Genecard, OMIM, DrugBank database, and constructing protein interaction network (PPI). Through the Network Analyzer tool of Cytoscape, the topology of the target was analyzed, the MCODE algorithm of the plug-in ClusterViz was used for cluster analysis, and the DAVID biological molecular function software was used to perform enrichment analysis. Results: The network analysis indicated that two prescriptions may play antidepressant roles through INS, AKT1, TP53, IL6, and CREB1 targets, involving neuroactive ligand-receptor interaction, cAMP signaling pathway, serotonergic synapse, calcium signaling pathway, and cholinergic synapse pathways. The unique antidepressant mechanism for Xiaoyao Powder is that PIK3CA, BDNF, PIK3R1, and NGF target the PI3K-Akt, calcium, and other signal pathways, and CCND1, PRKACA, GCLM, GCLC targeting oxytocin signaling pathway, cholinergic synapses, and other pathways is considered as Kaixin Powder unique antidepressive mechanism. Conclusion: Xiaoyao Powder and Kaixin Powder have similarities and differences in antidepressant targets due to their differences in composition, and the scientific connotation of “same disease with different treatments” is preliminarily clarified by the analysis of the target and the pathway.